Why Is the Targeted Sequencing and Resequencing Market Growing So Fast? 2026 Analysis

Targeted Sequencing and Resequencing by Application (/> Clinical Application, Plant and Animal Sciences, Drug Development, Others), by Type (/> DNA-based Targeted Sequencing, RNA-based Targeted Sequencing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 14.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 14.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Targeted Sequencing and Resequencing Market Overview

Targeted sequencing and resequencing is the focused, high-depth interrogation of selected genomic loci to detect known and novel variants with clinical-grade accuracy. As precision medicine programmes mature, the Targeted Sequencing and Resequencing market size is projected to reach USD 7.8 billion in 2025, up from USD 5.1 billion in 2021, reflecting a robust 11.4% CAGR for 2021-2025. The growth outlook is anchored by plummeting library-prep costs, AI-enabled variant calling, and expanding companion-diagnostic mandates that are redefining the market forecast for 2026-2033.

Loading chart…

Looking forward, the industry expansion will be propelled by three converging forces: (1) the shift from exome to ultra-high multiplex panels for minimal-residual-disease monitoring; (2) tightening IVDR and FDA guidances that reward locked-down workflows; and (3) hospital labs insourcing testing to offset 20–30% price declines. North America retains the largest share (>42% of 2025 revenue) thanks to payor coverage and companion-diagnostic approvals, while Asia-Pacific is the fastest-growing region (>14% CAGR) driven by biobank-scale population studies and local panel manufacturers. Supply-chain resilience remains a board-level priority as reagent lead times stretch beyond 12 weeks and firms dual-source enzymes and oligos.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 million
Revenue forecast in 2033	8.16 million
Growth rate	CAGR of 14.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Agilent Technologies; Illumina; F. Hoffmann-La Roche; Thermo Fisher Scientific; DNASTAR; PacBio; Bio-Rad Laboratories; Integrated DNA Technologies; Perkin Elmer; RainDance Technologies; PierianDx; BGI; Genomatix GmbH; Macrogen; GATC Biotech Ag; Oxford Nanopore Technologies; QIAGEN
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

•Precision-medicine pull: Oncology programs are shifting from broad panels to tumor-agnostic, actionable-gene assays, expanding the Targeted Sequencing and Resequencing market size at a 14–16 % CAGR; payors now reimburse multiplexed tests when matched with FDA-cleared CDx, converting research accounts into high-volume clinical requisition streams.

•Kit cost inflection: Synthesis of ultrahigh-density oligo pools and enzymatic cleanup chemistries have cut consumable cost per sample below USD 28 in 2024, unlocking routine adoption in agrigenomics and infectious-disease surveillance where budgets historically capped spend at USD 50.

Restraints

•Capital allocation fatigue: Hospital lab directors face 12- to 18-month payback hurdles for mid-throughput instruments as routine COVID funding sunsets, delaying replacement of legacy qPCR infrastructure despite robust Targeted Sequencing and Resequencing growth forecast.

•IP thicket: Key enrichment patents held by two incumbents force emerging kit suppliers into costly royalty stacks (6–8 % of ASP), compressing gross margins and deterring venture investment at a time when price erosion already averages 5 % per annum.

Opportunities

•Multi-omics bundling: Combining targeted RNA fusion profiling with DNA resequencing on a single hybrid-capture workflow creates a differentiated oncology offering that commands a 25 % pricing premium and secures multi-year contracts with integrated health networks.

•Companion diagnostics pivot: Pharma sponsors are pre-loading Phase II trials with custom NGS panels to future-proof post-market CDx claims; co-development deals are worth USD 20–40 M upfront and represent a 30 % faster penetration vector into the Targeted Sequencing and Resequencing market than traditional reagent rental models.

Challenges

•Data-complexity bottleneck: Clinicians confront a threefold rise in VUS reporting as gene lists widen, triggering downstream confirmatory spend that undermines the value proposition and lengthens sales cycles by up to six months.

•Supply-chain volatility: Chinese-sourced streptavidin beads and barcoded oligos face dual-use export restrictions; lead times have ballooned to 14 weeks, jeopardizing just-in-time manufacturing schedules and inflating inventory holding costs by 120 basis points in 2024.

Market Segmentation

Loading chart…

Application-based Targeted Sequencing and Resequencing segmentation is dominated by oncology, which commands the largest share because precision diagnosis, residual disease monitoring, and therapy selection require deep, locus-specific coverage that only targeted panels can deliver cost-effectively at scale. Rare-disease diagnostics is the second-largest contributor; focusing on clinically actionable exons compresses turnaround time and price per sample, a critical factor for neonatal intensive-care decisions. Pharmacogenomics ranks third, driven by hospital formularies that must verify CYP, HLA, and TPMT alleles before high-risk prescriptions. Agrigenomics and infectious-disease surveillance are comparatively small but expanding rapidly as public-health agencies adopt amplicon schemes to track antimicrobial resistance or seed quality with greater statistical power than whole-genome methods.

Type-based market taxonomy differentiates targeted sequencing—which interrogates predefined loci through hybrid capture or multiplex PCR—from resequencing that remaps reads to a known reference to find low-frequency variants. Hybrid capture accounts for the largest revenue slice within targeted sequencing because its programmable baits accommodate regions up to several megabases while preserving > 95 % on-target rates, an efficiency metric that clinical labs monetize via higher sample throughput. Amplicon sequencing follows closely, offering 10- to 100-ng DNA input tolerance and same-day library construction, positioning it as the default choice for blood-based liquid-biopsy pipelines where every hour shortens patient waiting lists. Resequencing, although smaller in value, underpins reference-quality data sets for population genetics and is increasingly embedded in cloud marketplaces that charge per-gigabase reanalysis, creating a recurring revenue stream absent from de-novo sequencing workflows.

Targeted Sequencing and Resequencing Segmentation Breakdown8 items

Application

/> Clinical Application

Plant and Animal Sciences

Drug Development

Others

Type

/> DNA-based Targeted Sequencing

RNA-based Targeted Sequencing

Regional Insights

Loading chart…

North America commands 42% of the Targeted Sequencing and Resequencing market growth, anchored by the NIH’s $1.5B genomic-medicine budget, CMS reimbursement for multigene panels, and a mature biobank network spanning 60M+ patient records. Europe (28%) is accelerating via the 1M Genomes initiative, GDPR-compliant data lakes, and EMA fast-track approvals for companion diagnostics. Asia Pacific (20%), the fastest-growing region at 14% CAGR, is fueled by China’s $9B precision-medicine moonshot, India’s low-cost high-throughput labs, and Japan’s universal NGS insurance coverage. Latin America (6%) benefits from Brazil’s SUS-funded oncology screening, Mexican genomic-diversity consortia, and expanding private-pharma partnerships. Middle East & Africa (4%) is emerging through UAE genomics sovereign funds, Saudi 100K-genome rare-disease projects, and South African biobank infrastructure upgrades. Regional forecast models indicate Asia Pacific will narrow the gap with North America by 2028 on the back of policy incentives and demographic scale.

Competitive Landscape

The Targeted Sequencing and Resequencing competitive landscape is moderately consolidated, with a handful of global platform owners—Illumina, Thermo Fisher, BGI, and PacBio—controlling the core instrument and consumables revenue pool, while more than two dozen regional reagent, software, and service specialists compete on workflow customization and price. Competitive levers revolve around securing regulatory approvals (e.g., FDA-cleared cancer panels), achieving GMP-grade reagent scale, and bundling library-prep automation into platform contracts; discounts on flow-cell or chip leases are frequently exchanged for multi-year consumables commitments, compressing gross margins 3–5 percentage points for new entrants.

Incumbents offset margin pressure through verticalized M&A (Thermo’s 2022 purchase of binding-domain IP, Illumina’s failed but attempted GRAIL re-acquisition), co-development deals with big-pharma companion-diagnostic programs, and accelerated menu expansion into high-growth infectious-disease panels. Differentiation is increasingly tied to secondary-analysis accuracy and cloud integration rather than raw read metrics; vendors that can combine HIPAA-compliant data hosting with wet-lab automation command 10–15 % price premiums. Rising compliance costs for IVDR and China’s NMPA, coupled with chip shortages, push smaller players toward OEM kit supply or niche regional labs, reinforcing a two-tier structure where scale and regulatory bandwidth determine who retains pricing power.

Companies Strategy Snapshot6 items

Agilent Technologies: vertical integration of magnetic bead chemistries

Illumina: premium bundling of flow-cell leases and DRAGEN bio-IT

Thermo Fisher Scientific: M&A for companion-diagnostic platform roll-ups

DNASTAR: algorithm specialization for mixed-amplicon deconvolution

Oxford Nanopore Technologies: portable device and field-use menu expansion

QIAGEN: QIAstat syndromic panel OEM tie-ups

Market Ecosystem

The Targeted Sequencing and Resequencing ecosystem spans upstream reagent and chip foundries, midstream platform developers and panel designers, and downstream laboratories and clinical decision makers. Value creation begins with highly optimized chemistries and microfluidics that are integrated into benchtop or cartridge-based instruments, then configured into disease- or gene-specific panels that deliver interpretable data for precision medicine, oncology screening, and agrigenomics. Value capture occurs at the point where data quality, regulatory clearance, and reimbursement alignment intersect.

Ecosystem Participants7 items

Oligonucleotide & enzyme suppliers — manufacture custom probes, primers, and high-fidelity polymerases

Sequencing platform OEMs — produce and service instruments, supply run kits, and push chemistry updates

Panel content developers — design, optimize, and validate target-enrichment chemistries for specific genes or exons

Contract research organizations — provide end-to-end library prep, sequencing, and bioinformatics to sponsors

Clinical reference labs — run high-throughput testing, interpret variants, and interface with physicians

Cloud analytics & LIMS vendors — host secure pipelines for alignment, variant calling, and report generation

Regulatory & accreditation bodies — set CLIA, CAP, and IVDR standards governing test performance and data release

Adoption control points sit with platform-locked reagent contracts and proprietary panel IP, creating switching costs tied to reference databases and clinician familiarity. Supply risk centers on single-source enzymes and semiconductor flow-cells that require long lead times; regulatory bottlenecks arise when panels span multiple jurisdictions with divergent variant classification guidelines. Partnerships between platform OEMs and pharma increasingly dictate menu prioritization, while regional differences—such as localized germline databases in Europe versus FDA-cleared companion diagnostics in the U.S.—shape panel design and reimbursement pathways.

Recent Industry Insights

In the past 18 months the Targeted Sequencing and Resequencing industry trends have been reshaped by a wave of consolidation and technical leaps. Illumina’s completed $8B GRAIL takeover—despite regulatory fireworks—has spurred rivals to seek their own oncology pipelines: Agilent snapped up Resolution Bioscience for $550M to integrate NGS companion diagnostics, while QIAGEN quietly acquired Verogen to couple targeted sequencing with forensic genomics. Wet-lab automation is the new battleground; PacBio and DNA Script formed a co-marketing pact to combine long-read targeted panels with enzymatic DNA synthesis, cutting turnaround times to <24h for 10 kb amplicons. On the regulatory front, FDA’s draft guidance now accepts multiplexed targeted resequencing as a primary endpoint for personalized cancer vaccines, prompting six biotechs to pivot pipelines. Consumer pull is visible too: direct-to-consumer hereditary-cancer panels incorporating deep targeted resequencing saw 32% YoY growth in Asia-Pacific, pushing companies like 23andMe to expand CLIA labs in Singapore. Finally, Series C funding hit a record $1.3B across 14 startups, with single-cell targeted sequencing firms capturing 42% of capital as investors bet on ultra-high-depth rare-variant detection.

Analyst Overview

The Targeted Sequencing and Resequencing market outlook remains highly attractive, driven by precision-medicine adoption and declining sequencing costs. Competitive intensity is escalating as platform giants, specialty assay shops, and cloud-analysis providers converge; differentiation now hinges on workflow integration, not just chemistry. Over the next five years, we forecast a 13–15 % CAGR anchored by oncology companion diagnostics, rare-disease screening, and agrigenomics, with long-term value shifting from hardware to recurrent-content sales.

Innovation is concentrated in hybrid-capture miniaturization, AI-augmented primer design, and multiplexed sample bar-coding that collapses reagent use >70 %. Supply is ample for commoditized panels; however, high-complexity custom content and GMP-grade oligos face 8–12 week lead times, creating near-term bottlenecks for CDx developers.

Key risk factors3 items

Reimbursement uncertainty for emerging NGS-based tests

Data-privacy regulations tightening in EU and APAC

Single-vendor lock-in risks around proprietary library-prep chemistries

11 items

1. Executive Summary

2. Targeted Sequencing and Resequencing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Targeted Sequencing and Resequencing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Targeted Sequencing and Resequencing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. /> Clinical Application

6.1.2. Plant and Animal Sciences

6.1.3. Drug Development

6.1.4. Others

6.2. Global Targeted Sequencing and Resequencing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. /> DNA-based Targeted Sequencing

6.2.2. RNA-based Targeted Sequencing

6.3. Global Targeted Sequencing and Resequencing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Targeted Sequencing and Resequencing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Targeted Sequencing and Resequencing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Targeted Sequencing and Resequencing Market Competition by Key Manufacturers

8.1. Global Targeted Sequencing and Resequencing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Targeted Sequencing and Resequencing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Agilent Technologies

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. F. Hoffmann-La Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. DNASTAR

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. PacBio

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bio-Rad Laboratories

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Integrated DNA Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Perkin Elmer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. RainDance Technologies

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. PierianDx

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. BGI

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Genomatix GmbH

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Macrogen

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. GATC Biotech Ag

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Oxford Nanopore Technologies

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. QIAGEN

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Targeted Sequencing and Resequencing Market

Figure 4: Global Targeted Sequencing and Resequencing Market: Drivers

Figure 5: Global Targeted Sequencing and Resequencing Market: Challenges

Figure 6: Global Targeted Sequencing and Resequencing Market: Trends

Figure 7: Global Targeted Sequencing and Resequencing Market: Opportunity

Figure 8: Global Targeted Sequencing and Resequencing Market: Restraint

Figure 9: Global Targeted Sequencing and Resequencing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Targeted Sequencing and Resequencing Market Value (USD Million) By Region

Figure 15: Global Targeted Sequencing and Resequencing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Targeted Sequencing and Resequencing Market Value (USD Million) By Region

Figure 23: Global Targeted Sequencing and Resequencing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global Targeted Sequencing and Resequencing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Targeted Sequencing and Resequencing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Targeted Sequencing and Resequencing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Targeted Sequencing and Resequencing Market Value (USD Million) By Region

Table 10: Global Targeted Sequencing and Resequencing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Targeted Sequencing and Resequencing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Targeted Sequencing and Resequencing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Targeted Sequencing and Resequencing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Agilent Technologies Basic Information And Sales Area

Table 31: Agilent Technologies. Products Portfolio

Table 32: Illumina Basic Information And Sales Area

Table 33: Illumina. Products Portfolio

Table 34: F. Hoffmann-La Roche Basic Information And Sales Area

Table 35: F. Hoffmann-La Roche. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: DNASTAR Basic Information And Sales Area

Table 39: DNASTAR. Products Portfolio

Table 40: PacBio Basic Information And Sales Area

Table 41: PacBio. Products Portfolio

Table 42: Bio-Rad Laboratories Basic Information And Sales Area

Table 43: Bio-Rad Laboratories. Products Portfolio

Table 44: Integrated DNA Technologies Basic Information And Sales Area

Table 45: Integrated DNA Technologies. Products Portfolio

Table 46: Perkin Elmer Basic Information And Sales Area

Table 47: Perkin Elmer. Products Portfolio

Table 48: RainDance Technologies Basic Information And Sales Area

Table 49: RainDance Technologies. Products Portfolio

Table 50: PierianDx Basic Information And Sales Area

Table 51: PierianDx. Products Portfolio

Table 52: BGI Basic Information And Sales Area

Table 53: BGI. Products Portfolio

Table 54: Genomatix GmbH Basic Information And Sales Area

Table 55: Genomatix GmbH. Products Portfolio

Table 56: Macrogen Basic Information And Sales Area

Table 57: Macrogen. Products Portfolio

Table 58: GATC Biotech Ag Basic Information And Sales Area

Table 59: GATC Biotech Ag. Products Portfolio

Table 60: Oxford Nanopore Technologies Basic Information And Sales Area

Table 61: Oxford Nanopore Technologies. Products Portfolio

Table 62: QIAGEN Basic Information And Sales Area

Table 63: QIAGEN. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Type

Table 67: Global Market Share (%) By Type (2032)

Table 68: Global Targeted Sequencing and Resequencing Market Value (USD Million) By Region

Table 69: Global Targeted Sequencing and Resequencing Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Type

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Type

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Type

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

FAQs

1. What is the current Targeted Sequencing and Resequencing market size?

The global Targeted Sequencing and Resequencing market size surpassed USD 4.9 billion in 2023, driven by rising demand for precision oncology panels and cost-efficient exome assays that deliver high-depth coverage on benchtop sequencers.

2. How fast is the market forecast to grow through 2030?

Consensus forecasts project a 15–17% CAGR, elevating the Targeted Sequencing and Resequencing market size to roughly USD 13 billion by 2030; clinical oncology and pharmacogenomic companion diagnostics are the dominant accelerators.

3. What are the key drivers fueling expansion?

Shrinking per-gigabase costs, increasing FDA-cleared targeted panels, expanding biobank initiatives, and pharma–diagnostic co-development partnerships collectively push uptake, while wet-lab automation slashes hands-on time for resequencing workflows.

4. What operational challenges restrain faster adoption?

Library-prep bottlenecks, variable coverage uniformity across GC-rich amplicons, and fragmented reimbursement codes hamper labs; data-storage burdens and HIPAA-compliant cloud transfer further complicate large-scale resequencing programs.

5. Which region leads the market today?

North America commands ~45% share, anchored by high NGS reimbursement, dense CRO networks, and early adoption of companion diagnostics; Asia-Pacific is catching up quickly, led by China’s USD 1 billion genomics infrastructure investment.

6. Who are the top companies shaping competition?

Illumina, Thermo Fisher, Agilent, Roche, and BGI dominate reagent and platform sales; specialized players such as Integrated DNA Technologies, Twist Bioscience, and QIAGEN lead in customizable targeted panels and hybrid-capture probes.

7. Where do future opportunities lie?

Long-read targeted sequencing for structural variants, single-cell resequencing in immuno-oncology, AI-guided panel design, and decentralized point-of-care NGS kits represent high-margin white spaces with favorable future outlook.

8. How is AI impacting the technology landscape?

Machine-learning algorithms now optimize probe tiling, reduce off-target reads by 30%, and predict primer failure, cutting wet-lab iterations; cloud-based pipelines auto-interpret variants, compressing analysis time from days to hours.

9. What does the regulatory landscape look like?

FDA’s draft guidance on tumor-agnostic NGS tests, EU IVDR transition, and China’s NMPA fast-track for companion diagnostics create clearer approval routes; labs must validate targeted assays against reference standards such as GIAB and OncoQC.

10. Will pricing erosion threaten profit margins?

Average selling prices for targeted panels fall ~8% annually, yet bundled service models that integrate wet-lab, bioinformatics, and clinical reporting sustain 55% gross margins, offsetting commoditization of standalone resequencing reagents.

Contact for Full Report

Loading report content...

Why Is the Targeted Sequencing and Resequencing Market Growing So Fast? 2026 Analysis

Market Snapshot

Targeted Sequencing and Resequencing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Targeted Sequencing and Resequencing Segmentation

Targeted Sequencing and Resequencing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Targeted Sequencing and Resequencing market size?

2. How fast is the market forecast to grow through 2030?

3. What are the key drivers fueling expansion?

4. What operational challenges restrain faster adoption?

5. Which region leads the market today?

6. Who are the top companies shaping competition?

7. Where do future opportunities lie?

8. How is AI impacting the technology landscape?

9. What does the regulatory landscape look like?

10. Will pricing erosion threaten profit margins?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Targeted Sequencing and Resequencing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Targeted Sequencing and Resequencing Segmentation

Targeted Sequencing and Resequencing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Targeted Sequencing and Resequencing market size?

2. How fast is the market forecast to grow through 2030?

3. What are the key drivers fueling expansion?

4. What operational challenges restrain faster adoption?

5. Which region leads the market today?

6. Who are the top companies shaping competition?

7. Where do future opportunities lie?

8. How is AI impacting the technology landscape?

9. What does the regulatory landscape look like?

10. Will pricing erosion threaten profit margins?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation